MedTrace Logo

Antibody Secreting Cell and Cyotokine Profiles in Neonates on ECMO

NCT00371241 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2020-11-05

No results posted yet for this study

Summary

Infants are placed on ECMO for correction of reversible respiratory failure. Often, because a few of the reasons for respiratory failure show us similar things in the baby, it is difficult to determine exactly which is causing the biggest problem. We are now capable of measuring certain cells and proteins in these infants that may help us more accurately diagnose the exact problem. We hypothesize that infants placed on ECMO will show unique antibody-secreting cells responses and patterns of cytokine and chemokine (protein) response to illness and to the ECMO circuit. If we find unique patterns to these cells or proteins, they may be able to predict outcomes or guide treatment of these infants.

Conditions

  • Persistent Fetal Circulation Syndrome
  • Diaphragmatic Hernia
  • Meconium Aspiration
  • Sepsis

Sponsors & Collaborators

  • Memorial Hermann Hospital

    collaborator OTHER

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • James M Murpy, PhD · University of Texas Health Science Center at Houston- Division of Infectious Diseases

Eligibility

Min Age
1 Day
Max Age
30 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00371241 on ClinicalTrials.gov